HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New York’s Age Restrictions On Weight Loss, Sports Supplement Sales Fail To Fly

Banning Sales To Minors Still Could Have Wings To Pass There, Other States

Executive Summary

New York legislation to restrict sales of weight loss and sports nutrition supplements to minors failed without reaching a vote before the end of the session. But the proposal will continue to be a challenge for industry in New York as well as around the country.

You may also be interested in...



States’ Proposals To Age-Restrict Sports Nutrition Sales Miss Targeted Problems But Hit Retailers

MA and NY lawmakers propose prohibiting sales to consumers under 18 of supplements, OTC drugs for weight loss and muscle building and imposing $2,000 fines for violations. Supplement industry trade groups say the laws would not help solve eating disorders but would hammer retailers.

Dinosaur Among The Unicorns: L'Oreal Talks Beauty Tech Innovation At VivaTech 2022

L’Oreal Group’s CEO referred VivaTech 2022 attendees to Yves Saint Laurent Beauty Scent-Sation, an electroencephalography-based headset that reads consumers’ emotional responses to different scent families, as an example of the firm’s beauty tech innovation that is personalizing the consumer experience, matching consumers with products, and distinguishing L’Oreal as a … err … “T-unicorn.”

US House Appropriators Seek Data On Fragrance Allergens In Cosmetics, ‘Balance’ In Sunscreen Regs

The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.

Topics

Latest News
UsernamePublicRestriction

Register

RS151429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel